Recent developments include: In January 2024, France-based SANOFI agreed to acquire a U.S.-based drug development project of INBRX-101 from the parent company Inhibrx Inc. for around 2.2 billion dollars to escalate the business of rare diseases. This acquisition will help to enhance the company’s revenues from the anti-inflammatory drugs and boost the R&D domain of the company. , In November 2023, AbbVie announced the agreement with ImmunoGen and its significant cancer therapy namely ELAHERE. This acquisition will accelerate AbbVie’s commercial and clinical expansion in the tumor section. In addition, ELAHERE is the first-in-class antibody-drug conjugate (ADC) which will help to supplement the ADCs division of AbbVie. , In 2022, Sanofi and AstraZeneca together developed the world’s first vaccine against bronchiolitis. AstraZeneca spent 585 euro million for manufacturing the product while Sanofi handled the marketing of the product. .

In 2023, the leading company within the French pharmaceutical industry was Sanofi Winthrop Industrie, a subsidiary of the Sanofi Group, with a French-based revenue of over nearly ** billion euros.

Forecast: Total Pharmaceutical Market in France 2024 - 2028 Discover more data with ReportLinker!

The French Active Pharmaceutical Ingredients (API) market, valued at approximately €1.5 billion in 2025, is projected to experience robust growth, driven by a compound annual growth rate (CAGR) of 6.10% from 2025 to 2033. This expansion is fueled by several key factors. The increasing prevalence of chronic diseases like cardiovascular conditions and cancer necessitates a higher demand for pharmaceuticals, consequently boosting the API market. Furthermore, growing R&D investments by pharmaceutical companies in France are leading to the development of innovative drugs and formulations, increasing the need for advanced APIs. The rise in outsourcing of API manufacturing to specialized companies due to cost efficiency and technological expertise is also contributing to market expansion. Specific growth within segments is expected to be driven by a preference towards branded drugs over generics in certain therapeutic areas, and significant demand for APIs used in oncology and cardiology treatments. The captive API segment will likely see considerable growth due to increased vertical integration by major pharmaceutical players. However, the market's growth is not without its challenges. Stringent regulatory requirements for API manufacturing and approval processes can create delays and increase production costs. Supply chain disruptions, particularly concerning raw materials and specialized chemicals, pose a significant risk. Fluctuations in currency exchange rates and global economic instability also pose headwinds to the consistent expansion of the market. Despite these constraints, the projected growth trajectory is overwhelmingly positive, indicating a strong outlook for the French API market over the next decade. The market's segmentation by business mode (captive vs. merchant), synthesis type (synthetic vs. biotech), drug type (generic vs. branded), and application area allows for a granular understanding of market dynamics and helps identify areas of greatest potential for investment and growth. Recent developments include: October 2022: MilliporeSigma opened a 700-square-meter (29,000-square-foot) commercial facility for its new Millipore CTDMO Services in France to produce monoclonal antibodies and other recombinant proteins. The CTDMO service spans pre-clinical to commercial phases, including testing, across multiple modalities, including mAbs, highly potent active pharmaceutical ingredients, antibody-drug conjugates, viral vector therapies, mRNA, and lipid nanoparticle formulation., July 2022: As part of a wider project funded by the 'France Relance' Plan, the Novasep-PharmaZell Group committed EUR 7.3 million in its Mourenx facility (southwestern France) to build a multipurpose pilot workshop inside one of its production units. The new industrial instrument will support the development of the Mourenx site and the ongoing need to produce active pharmaceutical ingredients (APIs), particularly the highly potent medicines (HPAPIs) used to treat cancer.. Key drivers for this market are: Increasing Prevalence of Infectious, Genetic, Cardiovascular, and Other Chronic Disorders, Increasing Adoption of Biologicals and Biosimilars; Rising Prevalence of Cancer and Increasing Sophistication in Oncology Drugs Research. Potential restraints include: Increasing Prevalence of Infectious, Genetic, Cardiovascular, and Other Chronic Disorders, Increasing Adoption of Biologicals and Biosimilars; Rising Prevalence of Cancer and Increasing Sophistication in Oncology Drugs Research. Notable trends are: Oncology Segment Expects to Register a Healthy CAGR.

This statistic shows the distribution of generic drugs in the French pharmaceutical market in 2018, according to value and volume. The share of generic molecules in the pharmaceutical market accounted for about ** percent of the total value of the pharmaceutical market for drugs listed by the ANSM.

The pharmaceutical product and preparations manufacturing industry has experienced volatile, albeit positive, development in recent years. The COVID-19 outbreak in 2020 skyrocketed the industry’s importance, with many manufacturers rushing to develop and patent COVID-19 vaccines and other related tests. Spiking hospital admissions during the height of the pandemic also heightened demand for various pharmaceutical products. Following the pandemic, chemical goods and production costs have become massively more expensive in the wake of the energy crisis in 2022. The Russian invasion of Ukraine significantly disrupted global energy markets. In combination with a surge in energy demand following the pandemic, energy prices increased as economies began to recover. The increased costs could not be passed on in full and had a negative impact on earnings as well as profit. Still, revenue is expected to climb at a compound annual rate of 2.4% over the five years through 2025 to reach €54.9 billion, including an estimated increase of 1.3% in 2025. Although EU pharma manufacturers are investing heavily in new treatment research and development, boosting industry growth, they are also facing intense competition from overseas suppliers, particularly from China and India, when it comes to selling intensive-care medical products. Overall, an ageing population across Europe is expanding the available market for manufacturers, with rising healthcare spending and programmes like EU4Health and the Innovation Healthcare 2030 plan supporting the industry. Innovative technologies, like the use of artificial intelligence in drug discovery and automation in manufacturing, are expected to cause revenue to increase at a compound annual rate of 1.5% over the five years to 2030, reaching €59.2 billion. Companies are likely to remain stagnant due to high competition and barriers to entry.

In the pharmaceuticals market in France in 2024, the oncology drugs segment generated the highest revenue, reaching approximately ************ U.S. dollars. The vaccines segment ranked second with around ************ U.S. dollars, while anti-diabetes drugs followed with about ************ U.S. dollars.

Pharmaceuticals in Dosage Market Size Value in France, 2021 Discover more data with ReportLinker!

Forecast: Pharmaceuticals in Dosage Market Size Value in France 2024 - 2028 Discover more data with ReportLinker!

The France Active Pharmaceutical Ingredients (API) Market is Segmented by Business Mode (Captive API and Merchant API), Synthesis Type (Synthetic and Biotech), Drug Type (Generic and Branded), and Application (Cardiology, Oncology, Pulmonology, Neurology, Orthopedic, Ophthalmology, and Other Applications). The report offers the value (in USD billion) for the above segments.

Discover the latest market trends and analysis of the thriving French diabetes drugs market. Explore growth projections, key players (Novo Nordisk, Sanofi, Eli Lilly), drug segment breakdowns (insulin, SGLT-2 inhibitors, GLP-1 agonists), and future opportunities in this dynamic sector. Get insights into market size, CAGR, and competitive landscape. Recent developments include: November 2023: Novo Nordisk has unveiled its plans for a significant investment in a production site located in France. This move aims to enhance the capacity and manufacturing capabilities of its highly successful anti-obesity medication. The Danish pharmaceutical powerhouse, Novo Nordisk, will be injecting a substantial amount of €2.1 billion into its existing facility in Chartres. This strategic decision also marks a notable collaboration with French President Emmanuel Macron., March 2022: Eli Lilly and Boehringer Ingelheim gained approval for heart failure treatment from the EU for sodium-glucose co-transporter-2-inhibitor, Jardiance (empagliflozin). Previously Jardiance gained a label expansion for treating heart failure in the US.. Notable trends are: The oral anti-diabetic drugs segment holds the highest market share in the France Diabetes Drugs Market in the current year.

This statistic shows the rate of penetration of generic drugs per unit in France from 2007 to 2018, depending on the size of the market. In 2018, the share of generics sold in the total medicines market was just over ** percent.

Snapshot img

Bio-Pharma Market Size 2025-2029

The bio-pharma market size is forecast to increase by USD 311.8 billion at a CAGR of 9% between 2024 and 2029.

The market is witnessing significant growth, driven by the increasing prevalence of health disorders and the rise in the production of vaccines. Biopharmaceuticals address a broad spectrum of diseases, such as cancer, diabetes, psoriasis, rheumatoid arthritis, genetic mutations, and various other conditions. The global health landscape is shifting, with an increasing focus on preventive healthcare and the development of innovative treatments. This trend is particularly pronounced in the Bio-Pharma sector, where the production of vaccines and specialized therapies is at an all-time high. However, the market also faces challenges, including the high cost of bio-pharmaceuticals. This cost burden can limit access to essential treatments for many patients, particularly in developing countries.
To succeed, they must focus on cost reduction strategies, such as process optimization and supply chain efficiencies, while also investing in research and development to bring innovative, cost-effective treatments to market. By addressing these challenges and leveraging the market's growth drivers, Bio-Pharma companies can position themselves for long-term success. The global population is aging, leading to an increase in chronic diseases such as cancer, type 2 diabetes, and cardiovascular diseases. Companies operating in this space must navigate these challenges while capitalizing on the market's opportunities.

What will be the Size of the Bio-Pharma Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market is experiencing significant trends and potential for growth, driven by the value proposition they offer in terms of cost savings and increased patient access to biologic therapies. The biosimilar market landscape is shaped by various factors, including patent expirations, regulatory approvals, and competition. Biosimilar analytical methods play a crucial role in demonstrating similarity between the reference biologic and the biosimilar, ensuring comparable bioavailability, pharmacodynamics, and pharmacokinetics. Clinical trials are essential to prove biosimilar efficacy, safety, and interchangeability, while regulatory agencies assess the quality attributes and manufacturing capabilities of biosimilars. The biosimilar patent landscape is complex, with numerous patents expiring and new ones being granted, impacting market share and competition.
The pricing of biosimilars is a critical consideration, with potential for significant cost savings for healthcare systems and patients. Biosimilar substitution and interchangeability are key aspects of market adoption, with regulatory approvals enabling automatic substitution in some cases. Safety and immunogenicity are essential considerations, as biosimilars may have unique risks compared to their reference biologics. Despite these challenges, the biosimilar market offers significant investment opportunities, as the demand for affordable biologic therapies continues to grow. The regulatory landscape is evolving, with a focus on streamlining approval processes and increasing transparency. Litigation is an ongoing concern, with patent disputes and regulatory challenges impacting market dynamics. The key driver for the market is the production of vaccines, which has gained significant momentum in recent years due to the ongoing COVID-19 pandemic.

How is this Bio-Pharma Industry segmented?

The bio-pharma industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product

  Monoclonal antibodies
  Recombinant growth factors
  Vaccines
  Recombinant hormones
  Others


Application

  Oncology
  Autoimmune disorder
  Metabolic disorder
  Hormonal disorder
  Others


Drug Class

  Proprietary biologics
  Biosimilars


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    UK


  APAC

    China
    India
    Japan
    South Korea


  South America

    Brazil


  Rest of World (ROW)

By Product Insights

The monoclonal antibodies segment is estimated to witness significant growth during the forecast period. Monoclonal antibodies, a segment of high-priced yet life-saving biologic drugs, hold a significant share in the market. Despite having lower sales volumes compared to other pharmaceutical products, the revenues generated from monoclonal antibodies are substantial due to their high price point. This market segment is poised for growth during the forecast period, with numerous companies investing heavi

France Pharmaceutical Manufacturing Market is expected to grow during 2025-2031

Germany was the leading pharmaceutical market in Europe with a total revenue of nearly 69 billion euros in 2023. France and Italy followed with revenues of 46.5 billion and 40.7 billion euros respectively. The top five were rounded off by Spain and Poland. German pharmaceutical marketWhen the revenue of the German pharmacy market is broken down, it is prescription drugs that account for the majority of the revenues. Prescription medication accounted for around 39 billion euros of revenue, followed by pharmacy-only drugs at some 3.5 billion euros. German pharmaceutical exportsOver a 13-year period, the value of pharmaceutical exports from Germany has skyrocketed. Increasing from approximately 18.8 billion euros in 2000 to some 113 billion euros in 2023. The leading destination for these exports is the United States, followed by the Netherlands and Switzerland.

Forecast: Pharmaceutical Goods Market Size Value in France 2024 - 2028 Discover more data with ReportLinker!

USD 3107.18 Million in 2024; projected USD 5816.72 Million by 2033; CAGR 7.28%.

The France Diabetes Drugs Market report segments the industry into Insulins (Basal Or Long Acting Insulins, Bolus Or Fast Acting Insulins, Traditional Human Insulins, and more.), Oral Anti-Diabetic Drugs (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, and more.), Non-Insulin Injectable Drugs (GLP-1 Receptor Agonists, and more.), and Combination Drugs (Insulin Combinations, and more.).

This statistic shows the total revenue of the French drug market from 2010 to 2018. In 2018, the global total revenue of this market was close to 56 billion euros.

Forecast: Pharmaceutical Industry Imports in France 2023 - 2027 Discover more data with ReportLinker!